|
Gastric Adenocarcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
BRD3 and UBAP1 are both involved in NPC carcinogenesis as confirmed through our previous studies and PTEN is a crucial tumor suppressor in many tumor types.
|
20053927 |
2010 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
BRD3 and UBAP1 are both involved in NPC carcinogenesis as confirmed through our previous studies and PTEN is a crucial tumor suppressor in many tumor types.
|
20053927 |
2010 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
BRD3 and UBAP1 are both involved in NPC carcinogenesis as confirmed through our previous studies and PTEN is a crucial tumor suppressor in many tumor types.
|
20053927 |
2010 |
|
Virus Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Brd3 interacts with both IRF3 and p300, increases p300-mediated acetylation of IRF3, and enhances the association of IRF3 with p300 upon virus infection.
|
28045112 |
2017 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
|
24231268 |
2013 |
|
Medullomyoblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
|
24231268 |
2013 |
|
Childhood Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
|
24231268 |
2013 |
|
Adult Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
|
24231268 |
2013 |
|
Desmoplastic Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
|
24231268 |
2013 |
|
Melanotic medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
|
24231268 |
2013 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
BET proteins such as Brd3 and Brd4 are chromatin-associated factors, which control gene expression programs that promote inflammation and cancer.
|
29603290 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
BET proteins such as Brd3 and Brd4 are chromatin-associated factors, which control gene expression programs that promote inflammation and cancer.
|
29603290 |
2018 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
BRD2, BRD3 and BRD4 proteins were detected in rheumatoid arthritis (RA) synovial tissue, expressed in both RASF and macrophages.
|
25467295 |
2016 |
|
MRSA - Methicillin resistant Staphylococcus aureus infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
Each blood culture sample was tested for the presence of MRSA by PCR analysis (SmartCycler) via detection of the mecA and orfX genes.
|
17368796 |
2007 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Tonometry
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses identify new loci influencing intraocular pressure.
|
29617998 |
2018 |
|
body fat percentage (physical finding)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomics of body fat percentage may contribute to sex bias in anorexia nervosa.
|
30593698 |
2019 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
|
28805821 |
2017 |
|
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
|
28805821 |
2017 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we tested the effect of JQ1-a small-molecule inhibitor of the chromatin readers BRD2, BRD3, BRD4 and BRDT-on brain function and show that JQ1 is able to enhance cognitive performance and long-term potentiation in wild-type animals and in a mouse model for Alzheimer's disease.
|
28949335 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, using both hormone-sensitive and triple-negative breast cancer (TNBC) model systems, we systematically altered EMT transcriptional profiles by manipulating individual BET proteins and found that BRD2 positively regulates EMT, whereas BRD3 and BRD4 repress this program.
|
29437854 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, using both hormone-sensitive and triple-negative breast cancer (TNBC) model systems, we systematically altered EMT transcriptional profiles by manipulating individual BET proteins and found that BRD2 positively regulates EMT, whereas BRD3 and BRD4 repress this program.
|
29437854 |
2018 |